Page 31 - AN-3-1

Advanced Neurology BTKi in brain diseases

BTK inhibitors in brain diseases, especially considering 2001;23(2-3):147-156.
that BTK inhibitors can enter and accumulate within doi: 10.1385/IR:23:2-3:147
the CNS, where they can directly affect immune cells.
Overall, therapeutic targeting of BTK in brain diseases 5. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor
shows promise and warrants further investigations. Future signaling pathway as a therapeutic target in CLL. Blood.
2012;120(6):1175-1184.
works may focus on the development of BTK inhibitors
as effective treatments for various brain diseases, which doi: 10.1182/blood-2012-02-362624
could provide additional valuable therapeutic options for 6. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation
patients. between inflammation and neurodegeneration in multiple
sclerosis brains. Brain. 2009;132(Pt 5):1175-1189.
Acknowledgments
doi: 10.1093/brain/awp070
None. 7. Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell

Funding antigen receptor signaling by a Syk/ITAM positive feedback
loop. Mol Cell. 2002;10(5):1057-1069.
None. doi: 10.1016/s1097-2765(02)00739-6

Conflict of interest 8. Whang JA, Chang BY. Bruton’s tyrosine kinase inhibitors for
the treatment of rheumatoid arthritis. Drug Discov Today.
The authors declare that they have no competing interests. 2014;198:1200-1204.

Author contributions doi: 10.1016/j.drudis.2014.03.028
Conceptualization: Qiang Liu, Han Jin 9. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s
tyrosine kinase in B cells and malignancies. Mol Cancer.
Writing – original draft: Hongying Hao 2018;17(1):57.
Writing – review & editing: Qiang Liu, Han Jin
doi: 10.1186/s12943-018-0779-z
Ethics approval and consent to participate 10. Martin E, Aigrot MS, Grenningloh R, et al. Bruton’s tyrosine
Not applicable. kinase inhibition promotes myelin repair. Brain Plast.
2020;5(2):123-133.
Consent for publication doi: 10.3233/bpl-200100
Not applicable. 11. Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I. Inhibition of
Bruton’s tyrosine kinase modulates microglial phagocytosis:
Availability of data Therapeutic implications for Alzheimer’s disease. J
Not applicable. Neuroimmune Pharmacol. 2019;143:448-461.
doi: 10.1007/s11481-019-09839-0
References
12. Geladaris A, Häusler D, Weber MS. Microglia: The missing
1. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved link to decipher and therapeutically control MS progression?
in X-linked agammaglobulinaemia is a member of the src Int J Mol Sci. 2021;22(7):3461.
family of protein-tyrosine kinases. Nature. 1993;361:226-33.
doi: 10.3390/ijms22073461
doi: 10.1038/361226a0
13. Neumann H, Kotter MR, Franklin RJM. Debris clearance
2. Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine by microglia: An essential link between degeneration and
kinase in B-cell development and function: A genetic regeneration. Brain. 2008;132(Pt 2):288-295.
perspective. Immunolog Rev. 2000;1751:120-127.
doi: 10.1093/brain/awn109
doi: 10.1111/j.1600-065X.2000.imr017504.x
14. Elberg G, Liraz-Zaltsman S, Reichert F, Matozaki T, Tal M,
3. Lindvall JM, Blomberg KEM, Valiaho J, et al. Bruton’s Rotshenker S. Deletion of SIRPalpha (signal regulatory
tyrosine kinase: Cell biology, sequence conservation, protein-alpha) promotes phagocytic clearance of myelin
mutation spectrum, siRNA modifications, and expression debris in Wallerian degeneration, axon regeneration,
profiling. Immunol Rev. 2005;203:200-215. and recovery from nerve injury. J Neuroinflammation.
2019;16(1):277.
doi: 10.1111/j.0105-2896.2005.00225.x
doi: 10.1186/s12974-019-1679-x
4. Khan WN. Regulation of B lymphocyte development
and activation by Bruton’s tyrosine kinase. Immunol Res. 15. Kirkley KS, Popichak KA, Afzali MF, Legare ME, Tjalkens

Volume 3 Issue 1 (2024) 7 https://doi.org/10.36922/an.2184